Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients
| العنوان: | Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients |
|---|---|
| المؤلفون: | Helena Katchman, Inbal Houri, Merav Ben-Yehoyada, Eugene Katchman, Liane Rabinowich, Dan Turner, Sharon Levi, Roni Baruch, Oren Shibolet, Nir Lubezky, Tami Halperin, Ayelet Grupper |
| المصدر: | Journal of Hepatology |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | 0301 basic medicine, Male, medicine.medical_treatment, Liver transplantation, Antibodies, Viral, Kidney Function Tests, primary biliary cholangitis, PBC, Alcoholic liver disease, ALD, Serology, Solid organ transplant, SOT, 0302 clinical medicine, Immunogenicity, Vaccine, Coronavirus Disease 2019, COVID-19, Risk Factors, SARS-CoV-2 vaccine, Calcineurin inhibitors, CNIs, Israel, Pfizer-BioNTech BNT162b2, Primary sclerosing cholangitis, PSC, education.field_of_study, Diabetes mellitus, DM, Immunogenicity, Vaccination, Antibody titer, Middle Aged, Hepatocellular carcinoma, HCC, 030211 gastroenterology & hepatology, Female, Hypertension, HTN, Immunosuppressive Agents, medicine.medical_specialty, COVID-19 Vaccines, Population, Body Mass Index, BMI, Article, standard deviation, SD, 03 medical and health sciences, non-alcoholic statohepatitis, NASH, Internal medicine, medicine, Humans, Serologic Tests, Liver Transplant, LT, education, Adverse effect, BNT162 Vaccine, Immunosuppression Therapy, Hepatology, business.industry, SARS-CoV-2, COVID-19, eGFR, Chronic Kidney Disease, Vaccine efficacy, Liver Transplantation, 030104 developmental biology, nucleocapsid (N) protein, Estimated glomerular filtration rate, autoimmune hepatitis, AIH, Immunoglobulin G, Mycophenolate mofetil, MMF, CKD, spike (S) protein, business |
| الوصف: | Background and aims Two SARS-CoV-2 mRNA vaccines were approved to prevent COVID-19 infection, with reported vaccine efficacy of 95%. Liver transplant (LT) recipients are at risk for lower vaccine immunogenicity and were not included in the registration trials. We assessed vaccine immunogenicity and safety in this special population. Methods LT recipients followed at the Tel-Aviv Sourasky Medical Center and healthy volunteers were tested for SARS-CoV-2 IgG antibodies directed against the Spike-protein (S) and Nucleocapsid-protein (N) 10-20 days after receiving the second Pfizer-BioNTech BNT162b2 SARS-CoV-2 vaccine dose. Information regarding vaccine side effects and clinical data was collected from patients and medical records. Results Eighty LT recipients were enrolled. Mean age was 60 years and 30% were female. Twenty-five healthy volunteer controls were younger (mean age 52.7 years, p=0.013) and mostly female (68%, p=0.002). All participants were negative for IgG N-protein serology, indicating immunity did not result from prior COVID-19 infection. All controls were positive for IgG S-protein serology. Immunogenicity among LT recipients was significantly lower with positive serology in only 47.5% (p Graphical abstract |
| تدمد: | 1600-0641 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c612eab431c5608a8ac2b37fff82867Test https://pubmed.ncbi.nlm.nih.gov/34393073Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....7c612eab431c5608a8ac2b37fff82867 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 16000641 |
|---|